Vitalibis, Inc. Stock

VCBD

US92849U2042

Pharmaceuticals

Market Closed - OTC Markets 15:16:39 2026-06-04 EDT			5-day change	1st Jan Change
1.500 ^USD	+25.00%		+900.00%	-47.37%

25-10-14	Zhejiang Bayi Electronics Technology Co., Ltd. entered into a non-binding letter of intent to acquire Vitalibis, Inc..	CI
21-09-02	Vitalibis, Inc. Bankruptcy Case Dismissed	CI

Vitalibis, Inc. engages in the development, sale, and distribution of hemp oil-based products that contain naturally occurring cannabinoids, such as cannabidiol (CBD). The Company markets consumer products containing full spectrum phytocannabinoid-rich hemp oil under the Vitalibis brand across various market sectors, including wellness and personal care. It distributes approximately eight products under its brand. It also sells water-soluble, full spectrum phytocannabinoid-rich hemp powder with naturally occurring CBD to various customers in the United States who use these products for resale. The Company has also started offering non-exclusive leases of its technology back-end through a Software as a Service (SaaS) platform. This platform, branded as Vitalibis, provides hosting, technical services, and a comprehensive e-commerce affiliate application as part of its SaaS offerings.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume

Real-time OTC Markets

More quotes

Stock Market
Stocks
VCBD Stock

-40%: Exceptional extension

SEIZE THE OFFER!

Market Cap	430K 375K 354K 321K 602K 41.24M 605K 4.24M 1.64M 20.97M 1.61M 1.58M 67.47M	P/E 2018	-21.3x	P/E 2019	-0.95x
Enterprise Value	1.53M 1.33M 1.26M 1.14M 2.14M 146M 2.15M 15.05M 5.81M 74.45M 5.73M 5.61M 240M	EV / Sales 2018	949,389,161x	EV / Sales 2019	25,985,979x
Free-Float	54.43%	Yield 2018 *	-	Yield 2019	-

25-10-14	Zhejiang Bayi Electronics Technology Co., Ltd. entered into a non-binding letter of intent to acquire Vitalibis, Inc..	CI
21-09-02	Vitalibis, Inc. Bankruptcy Case Dismissed	CI
21-08-02	Motion for Case Dismissal Filed for Vitalibis, Inc.	CI
20-11-18	Disclosure Statement Conditionally Approved for Vitalibis, Inc.	CI
20-11-18	Reorganization Plan and Disclosure Statement Filed by Vitalibis, Inc.	CI
20-11-17	Vitalibis, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	CI
20-08-14	Vitalibis, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	CI
20-06-15	Vitalibis, Inc. Filed for Bankruptcy	CI
20-05-15	Vitalibis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
20-04-01	Vitalibis, Inc. Alliance with Bruce Lee Beverage by Offering Actual Being™ Focus Adaptogen + Superfood Herbal Supplement	CI
20-03-13	Vitalibis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	CI
20-03-12	Vitalibis, Inc. Auditor Raises 'Going Concern' Doubt	CI
20-01-28	Vitalibis, Inc. Launches CBD+ Skincare Product Line	CI

21-09-10	VITALIBIS, INC. : Other Events (form 8-K)	AQ
20-11-17	VITALIBIS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
20-08-14	VITALIBIS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	AQ
20-06-16	VITALIBIS, INC. : Bankruptcy or Receivership (form 8-K)	AQ
20-06-03	VITALIBIS, INC. : Other Events (form 8-K)	AQ

1 day	+25.00%
1 week	+900.00%
Current month	+900.00%
1 month	+900.00%
3 months	-25.00%
6 months	-61.54%
Current year	-47.37%

Current year	0.03	6.75
1 year	0.03	6.75
3 years	0	6.75
5 years	0	15
10 years	0	7,364.63

Vitalibis, Inc. Stock

Stocks

VCBD

US92849U2042

Pharmaceuticals

Valuation: Vitalibis, Inc.

Chart: Vitalibis, Inc.

Latest news: Vitalibis, Inc.

Press Releases: Vitalibis, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Vitalibis, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VITALIBIS, INC.	+25.00%	+900.00%	-23.07%	+400.03%	49.46K
ELI LILLY AND COMPANY	+0.04%	+3.34%	+53.32%	+102.40%	1,028B
JOHNSON & JOHNSON	-0.09%	+1.66%	+53.24%	+65.73%	651B
ABBVIE INC.	-0.02%	+2.66%	+18.65%	+71.84%	466B
ROCHE HOLDING AG	-1.22%	+3.66%	+34.59%	+39.32%	346B
NOVARTIS AG	-0.79%	+2.73%	+17.73%	+23.91%	266B
ASTRAZENECA PLC	+0.58%	+6.76%	+10.58%	+14.16%	259B
AMGEN INC.	+1.55%	+2.20%	+35.12%	+42.07%	208B
NOVO NORDISK A/S	+0.79%	+1.84%	-27.55%	-57.51%	191B
GILEAD SCIENCES, INC.	-0.52%	+4.45%	+31.57%	+97.98%	186B
Average	+2.53%	+2.93%	+20.42%	+79.99%	360.17B
Weighted average by Cap.	-0.04%	+3.09%	+34.84%	+61.41%

	2018	2019
Net sales	0.05 0.04 0.04 0.04 0.07 4.93 0.07 0.51 0.2 2.5 0.19 0.19 8.06	0.3 0.26 0.25 0.23 0.42 29.09 0.43 2.99 1.15 14.79 1.14 1.11 47.59
Net income	-2.23M -1.94M -1.83M -1.67M -3.12M -214M -3.13M -21.98M -8.48M -109M -8.37M -8.19M -350M	-6.85M -5.97M -5.64M -5.12M -9.59M -657M -9.63M -67.52M -26.06M -334M -25.72M -25.15M -1.07B
Net Debt	-161K -140K -132K -120K -225K -15.41M -226K -1.58M -611K -7.83M -603K -590K -25.21M	1.1M 956K 903K 820K 1.54M 105M 1.54M 10.81M 4.17M 53.48M 4.12M 4.03M 172M